Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease

J Neurol Sci. 2017 Jan 15:372:288-293. doi: 10.1016/j.jns.2016.11.068. Epub 2016 Dec 1.

Abstract

Objective: To investigate the cortical metabolic alterations that precedes longitudinal cognitive decline in Parkinson's disease (PD).

Methods: We analyzed the data of 46 PD patients who did not have dementia at baseline and completed 3-year follow-up. Based on the results of general cognitive, memory and visuospatial tests, patients were classified into cognitively normal PD (PD-CogNL), PD with mild cognitive impairment (PD-MCI), and PD dementia (PDD). The regional cerebral glucose metabolism at rest was measured using 18F-fluorodeoxyglucose positron emission tomography. Voxel-wise effect size analyses were performed to delineate abnormal metabolic patterns associated with changes in cognitive status in PD.

Results: At baseline, 29 patients had PD-CogNL, and 17 patients had PD-MCI. At follow-up, 28 patients had PD-CogNL, 12 patients had PD-MCI, and 6 patients developed PDD. Seventeen of 29 PD-CogNL patients remained to be PD-CogNL, and 9 PD-CogNL patients converted to PD-MCI. Eleven PD-MCI patients reverted to normal cognition during follow-up. 3 PD-CogNL and 3 PD-MCI patients developed PDD. Cognitively stable PD-CogNL group had frontal predominant hypometabolism. PDD converters showed parieto-occipital hypometabolism at baseline regardless of whether a patient's initial cognitive status is PD-CogNL or PD-MCI.

Conclusions: Parieto-occipital hypometabolism is a good predictor of early dementia conversion in PD.

Keywords: Cognitive reversion; Cortical glucose metabolism; Dementia conversion; Longitudinal study; PD-MCI.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cerebral Cortex / diagnostic imaging
  • Cerebral Cortex / metabolism*
  • Cognition Disorders / diagnostic imaging
  • Cognition Disorders / etiology*
  • Cross-Sectional Studies
  • Dementia / etiology
  • Female
  • Fluorodeoxyglucose F18 / metabolism
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / pathology*
  • Positron-Emission Tomography
  • Severity of Illness Index

Substances

  • Fluorodeoxyglucose F18